References:
1. Anon: USPDI: Drug Information for the Health Care Professional, 17th ed. US Pharmacopeial Convention Inc, Rockville, MD; 1997.
2. Anon: American Academy of Clinical Toxicology; European Association of Poison Centers and Clinical Toxicologists: Position statement: single-dose activated charcoal. J Toxicol Clin Toxicol 1997; 35:721-741.
3. FDA: Poison treatment drug product for over-the-counter human use; tentative final monograph. Fed Register 1985; 50:2244-2262
4. Product information: Precose(R), acarbose. Bayer Corporation, West Haven, CT; 1998
5. North DS, Peterson RG & Krenzelok EP: Effect of activated charcoal administration on acetylcysteine serum levels in humans. Am J Hosp Pharm 1981; 38:1022-1024.
6. Neuvonen PJ, Elfving SM & Elonen E: Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man. Eur J Clin Pharmacol 1978; 13:213-218.
7. Product Information: Ipecac syrup. Eli Lilly and Company, Indianapolis, IN; 1989
8. Product information: Arava(TM), leflunomide. Hoechst Marion Roussel, Inc, Kansas City, MO; 1998
9. El-Bahie N, Allen EM, Williams J et al: The effect of activated charcoal and hyoscine butylbromide alon and in combination on the absorption of mefenamic acid. Br J Clin Pharmacol 1985; 19:836-838.
10. Product information: Glyset(TM), miglitol. Bayer Corporation, West Haven, CT; 1999.
11. Karkkainen S & Neuvonin PJ: Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics. Int J Clin Pharmacol Ther Toxicol 1985; 23:219-225
12. Product information: Zyprexa(TM), olanzapine. Eli Lilly and Company, Indianapolis, IN; 1999.
13. GrebWH, Buscher G, Dierdorf HD et al: Ability of charcoal to prevent absorption of paroxetine. Acta Psychiatr Scand 1989; 80 (suppl 350):156-157.
14. Bachrach WH & Hofmann AF: Ursodeocycholic acid in the treatment of cholesterol cholelithiasis (Part I). Dig Dis Sci 1982; 27:737-761.
15. Product information: Charcocaps(R), activated charcoal. Requa,Inc, Greenwich, CT; 1997.
16. Minocha A, Wiley SH, Chabbra DR et al: Superior efficacy of sorbitol cathartics in poisoned patients. AAPCC/AACT/AMBT/CAPCC Annual Scientific Meeting, Santa Fe, New Mexico, September 25-30 1986b, Abstract 112.
17. Watson WA, Guy JC & Leighton J: The incidence of emesis after activated charcoal in emergency room patients. AAPCC/AACT/ABMT/CAPCC Annual Scientific Meeting, Santa Fe, New Mexico, September 25-30, Abstract 132.
18. Dockstrader LL, Lawrence RA & Bresnick HL: Home administration of activated charcoal: feasibility and acceptance. AAPCC/AACT/ABMT/CAPCC Annual Scientific Meeting, Santa Fe, New Mexico, September 25-30, 1986, Abstract 1.
19. Mauro LS, Nawarskas JJ & Mauro VF: Misadventures with activated charcoal and recommendations for safe use. Ann Pharmacother 1994; 28:915-924.
20. Neuvonen PJ, Kivisto K & Hirvisalo EL: Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. Br J Clin Pharmacol 1988; 25:229-233.
21. Product Information: Myfortic(R), mycophenolic acid delayed-release tablets. Novartis Pharmaceuticals Corporation, East Hanover, NJ, 02/2004.
22. Actidose-Aqua(TM), activated charcoal suspension. Paddock Laboratories, Inc. Minneapolis, MN 2004.